Female Sexual Dysfunction
Conditions
Brief summary
The decrease or absence sexual desire and arousal is the alteration of the sexual sphere that women most commonly refer to in adulthood and old age. Many women can refer a decrease or absence of desire and / or arousal without having the disorder typified in the DSM-5, but that can cause discomfort, worry and relationship problems in their day to day. Libicare® is a food supplement whose ingredients could have positive effects on the improvement of sexual function in women with low desire and arousal levels. The main ingredients of Libicare® are: * Trigonella Foenum-graecum (Trigonella) (1) * Tribulus Terrestris (Tribulus) (2) * Turnera Diffusa (Damiana) (3)
Detailed description
The main objective is to describe the effectivity of LIBICARE® in the improvement of desire and sexual arousal in women between 45 and 65 years old, in real life. The secondary objectives of the study are: * Evaluation of the 6 domains of the EVAS-M scale at 2 and 4 months of treatment. * Assessment of the safety of LIBICARE® by collecting serious and non-serious adverse events. * Evaluation of patient satisfaction with treatment at 2 and 4 months of treatment. * Therapeutic compliance in taking the food supplement at 2 and 4 months of treatment. * Study of the hormonal variation in relation to the values of total testosterone, free testosterone and SHBG, at the beginning, at 2 months and at 4 months of treatment, in those patients in which it is determined by routine clinical practice. * To evaluate the degree of usefulness of the EVAS-M scale in clinical practice after 4 months of treatment.
Interventions
OTHERPatients' data (baseline characteristics, clinical and outcomes) from routine care visits
Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
Sponsors
Procare Health Iberia S.L.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Women between 45 and 65 years old, both ages included. * Women who refer decreased desire and / or sexual arousal. * Women who will receive LIBICARE® by prescription of their doctor regardless of their participation or not in the study. * Women who have given their informed consent in writing.
Exclusion criteria
* Women who suffer or have suffered breast cancer. * Women in anticoagulant treatment. * Women who, in the opinion of the researcher, cannot follow the study procedures. * Women not be able to understand the nature of the study, the procedures to follow or who are not authorized to sign an informed consent * Pregnant or lactating women * Women with allergies to any of the components of Libicare®
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To describe the effectiveness of LIBICARE® in improving sexual desire and arousal in women between 45 and 65 years of age, in real life. | 4 month | The effectiveness will be the increase in the score of the EVAS-M scale that will be provided to patients in the visita during the follow-up visits. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the safety of LIBICARE® by collecting serious and non-serious adverse events. | at 4 months of treatment | The safety that will be defined by the serious and non-serious adverse reactions collected throughout the study. |
| Evaluation of patient satisfaction with treatment at 2 and 4 months of treatment. | at 2 and 4 months of treatment | Evaluation of patient satisfaction with treatment using the Likert scale |
| Evaluation of the 6 domains of the EVAS-M scale at 2 and 4 months of treatment. | at 2 and 4 months of treatment | Evaluation of the 6 domains of the EVAS-M scale (Escala de Valoración de la Actividad Sexual en la mujer in Spanish, score from 2 to 60 points) at 2 and 4 months of treatment |
| Study of the hormonal variation in relation to the values of total testosterone, free testosterone and SHBG, at the beginning, at 2 months and at 4 months of treatment, in those patients in which it is determined by routine clinical practice. | at 0, 2 and 4 months of treatment | Study of the hormonal variation in relation to the values of total testosterone, free testosterone and SHBG, at the beginning, at 2 months and at 4 months of treatment, in those patients in which it is determined by routine care |
| To evaluate the degree of usefulness of the EVAS-M (ESCALA DE VALORACION DE LA ACTIVIDAD SEXUAL in Spanish) scale in clinical practice after 4 months of treatment. | at 4 months | Usefulness of using the EVAS-M scale in clinical practice (last visit) |
| Therapeutic compliance in taking the food supplement at 2 and 4 months of treatment. | at 2 and 4 months of treatment | Therapeutic compliance will continue to be adjusted as much as possible to routine clinical practice using the Likert scale |
Countries
Spain
Outcome results
None listed